In fact, researchers have proved that CD8+ T cells and the widely used PD-1 therapy significantly improve prognosis of HCC patients (Iwai et al., 2002), whereas CD4+ T cells are also components of activated CD8+ T cells (Borst et al., 2018). This evidence concerns the gene CD8A and hepatocellular carcinoma.